

However, even when commercial packages are used, there are a number of features that should be present before neural computing can be used to advantage. The problem must be numeric in nature, and reasonable quantities of data should be available to train an adequate model. The greatest benefits are achieved for multidimensional problems where it is difficult to express any analytic model and difficult to abstract the rules by any other mechanism than neural computing. It helps if the problem is of practical importance, is part of the organization's essential activity, and meets a real business need. Pharmaceutical formulation meets these criteria well, and neural computing can be expected to provide significant benefits in industry in the future.

REFERENCES

- [1] R. C. Rowe, E. A. Colbourn, *Pharm. Tech. Eur.* **9** (1996) 46-55
- [2] L. A. Zadeh, *Fuzzy sets. Information and Control* **8** (1965) 338-353
- [3] K. M. Bossley, *Neurofuzzy Modelling Approaches in System Identification*, PhD Thesis, University of Southampton, UK, 1997
- [4] J. H. Holland, *Adaptation in Natural and Artificial Systems*, The University of Michigan Press, Ann Arbor, USA (1975)
- [5] J. R. Koza, *Genetic Programming - On the Programming of Computers by Means of Natural Selection*, MIT Press, Cambridge, MA, USA, 1992
- [6] W. H. Verduin, *Better Products Faster - A Practical Guide to Knowledge-Based Systems for Manufacturers*, Irwin Professional Publishers, USA, 1994
- [7] M. Turkoglu, R. Ozarslan, A. Sakr, *Eur. J. Pharm. Biopharm.* **41** (1995) 315-322
- [8] J. G. Kesavan, G. E. Heck, *Pharm. Dev. Technol.* **1** (1996) 391-404
- [9] E. A. Colbourn, R. C. Rowe, *Pharm. Tech. Eur.* **8** (1996) 46-55
- [10] R. C. Rowe, E. A. Colbourn, *Pharm Tech Eur.* **12** (2000) 24-27
- [11] J. Bourquin, H. Schmidli, P. van Hoogevest, H. Leuenberger, *Pharm. Dev. Technol.* **2** (1997) 111-121
- [12] J. Bourquin, H. Schmidli, P. van Hoogevest, H. Leuenberger, *Eur. J. Pharm. Sci.* **6** (1998) 287-300
- [13] J. Bourquin, H. Schmidli, P. van Hoogevest, H. Leuenberger, *Eur. J. Pharm. Sci.* **7** (1998) 5-16
- [14] J. Bourquin, H. Schmidli, P. van Hoogevest, H. Leuenberger, *Eur. J. Pharm. Sci.* **7** (1998) 17-28
- [15] A.P. Plumb, R.C. Rowe, P. York, M. Brown, *Eur. J. Pharm. Sci.* **25** (2005) 395-405
- [16] Q. Shao, R. C. Rowe, P. York, *Eur. J. Pharm. Sci.* **28** (2006) 394-404
- [17] K. Rocksloh, F.R: Rapp, S. Abu Abed, W. Mueller, M. Reher, G. Gauglitz, P. C. Schmidt, *Drug Dev. Ind. Pharm.* **25** (1999) 1015-1025
- [18] Q. M. Do, G. V. Dang, N. Q. Le, *Tap Chi Duoc Hoc* **6** (2000) 16-19
- [19] U. Chen, S. Thosor, R. Forbess, M. Kemper, R. L. Rubinovitz, A. J. Shukla, *Drug Dev. Ind. Pharm.* **27** (2001) 623-631
- [20] P. M. Sathe, J. Venitz, *Drug Dev. Ind. Pharm.* **29** (2003) 349-355
- [21] N. O. Lindberg, E. A., Colbourn, *Pharm. Tech. Eur.* **16** (2004) 35-39
- [22] R. Zolotariou, J. Anwar, *J. Pharm. Pharmacol.* **50** (1998) 190
- [23] H. Sunada, Y. Bi, *Powder Technol.* **122** (2002) 188-198
- [24] S. Agatonovic-Kustrin, B. D. Glass, M.H. Wisch, R.G. Alany, *Pharm. Res.* **20** (2003) 1760-1765
- [25] A. Mendyk, R. Jachowicz, *Expert Sys. Appl.* **28** (2005) 285-294
- [26] A. Mendyk, R. Jachowicz, *Expert Sys. Appl.* **32** (2007) 1124-1131
- [27] A. P. Plumb, R. C. Rowe, P. York, C. Doherty, *Eur. J. Pharm. Sci.* **16** (2002) 281-288
- [28] A. P. Plumb, R. C. Rowe, P. York, C. Doherty, *Eur. J. Pharm. Sci.* **18** (2002) 259-266
- [29] R. C. Rowe, C. G. Venglar, *Pharm. Sci. Technol. Today* **2** (1999) 495-497
- [30] Y. Chen, W. McCall, A. Baichwal, M.C. Meyer, *J. Control. Release* **59** (1999) 33-41
- [31] D. Zupancic Boga, F. Vrecar, F. Kozjek, *Eur. J. Pharm. Sci.* **5** (1997) 163-170
- [32] K. Takayama, A. Morva, M. Fujikawa, Y. Hattori, Y. Obata, T. Nagai, *J. Control. Release* **68** (2000) 175-186
- [33] S. Ibric, M. Jovanovic, Z. Djuric, J. Parojcic, Lj. Solomun, *J. Control. Release* **82** (2002) 213-222
- [34] S. Ibric, M. Jovanovic, Z. Djuric, J. Parojcic, S.D. Petrovic, Lj. Solomun, B. Stupar, *Pharm. Sci. Tech.* **4** (2003) 62-70
- [35] S. Ibric, M. Jovanovic, Z. Đurić, J. Parojčić, Lj. Solomun, B. Lučić, *J. Pharm. Pharmacol.* **59** (2007) 745-750
- [36] J. Parojčić, S. Ibric, Z. Djurić, M. Jovanovic, O. I. Corrigan, *Eur. J. Pharm. Sci.* **30** (2007) 264-272
- [37] M. M. Leane, I. Cumming, O. Corrigan, *Pharm. Sci. Technol.* **4** (2003) 218-229
- [38] T. Wu, W. Pao, J. Chen, R. Shang, *Drug Dev. Ind. Pharm.* **26** (2000) 211-215
- [39] K.K. Peh, C.P. Lim, S.S. Qwek, K.H. Khoti, *Pharm. Res.* **17** (2000) 1386-1398
- [40] S.S. Qwek, C.P. Lim, K.K. Peh, *Int. J. Comp. Intel. Appl.* **1** (2001) 187-292
- [41] W.Y. Goh, C.P. Lim, K.K. Peh, K. Subari, *Neural Comput. Appl.* **10** (2002) 311-317
- [42] S. Vaithiyalingam, A.A. Zaghloul, I.K. Reddes, M.A. Khan, *Pharm. Tech.* **24** (2000) 60-72
- [43] S. Vaithiyalingam, M.A. Khan, *Int. J. Pharm.* **234** (2002) 179-193
- [44] M. Turkoglu, H. Varol, M. Celikok, *Eur. J. Pharm. Biopharm.* **57** (2004) 277-286
- [45] A. Ghaffari, H. Abdollahi, M.R. Khoshayand, I. Soltani Bozchalooi, A. Dadgar, M. Rafiee-Tehrani, *Int. J. Pharm.* **327** (2006) 126-138
- [46] V. Pillay, M.P. Danckwerts, *J. Pharm. Sci.* **91** (2002) 2559-2570
- [47] C. Rees, *Neural Computing—Learning Solutions—User Survey*. Department of Trade and Industry, London, UK, 1996.
- [48] R. C. Rowe, R. J. Roberts, *Intelligent software for product formulation*, Taylor and Francis, London, 1998.